ARTICLE | Clinical News
iCo-009 regulatory update
October 4, 2010 7:00 AM UTC
FDA granted Orphan Drug designation for iCo's iCo-009 to treat visceral leishmaniasis. The oral amphotericin B formulation is in preclinical testing to treat fungal and parasitic infections. ...